Georgia Eye Partners Becomes One of the First Practices in the United States To Offer New EVO Visian ICL Procedure
Georgia Eye Partners is proud to announce an expansion of its services to include EVO Visian® ICL, an innovative technology recently approved by the FDA, which corrects nearsightedness without the use of glasses or contact lenses.
Doctors Andrew Feinberg and Evan D. Schoenberg at Georgia Eye Partners are pleased to be two of the first select doctors throughout the United States to offer the procedure to their patients. There are only 300 doctors (approximately) throughout the country that are currently trained and approved to perform this procedure.
The practice remains committed to implementing the latest and greatest in visual corrective surgery and was previously one of the first throughout the country to also implant earlier versions of the Visian ICL.
What Is EVO ICL?
EVO Visian® ICL (as also known as “EVO”) is an evolution in visual correction surgery, providing patients with freedom from the inconvenience, discomfort, and expense that often comes from contact lenses and glasses.
EVO ICL is an implantable lens positioned just below the surface of the eye to correct nearsightedness (both myopia and myopia with astigmatism). The procedure was designed to be even more comfortable for the patient than earlier versions of the Visian ICL and a faster, more efficient procedure for surgeons than traditional laser surgeries. The collamer base of the lens material is 100 percent biocompatible and was created to function in harmony with your body’s chemistry.
EVO ICL Patient Satisfaction
Myopia, commonly known as nearsightedness, is the most common vision problem in the world, affecting approximately 1.9 billion people. That number is estimated to increase by 50 percent by the year 2050.
Thanks to the EVO Visian® ICL procedure, people have been granted the flexibility to live more active lifestyles and enjoy an improved quality of life.
“I had been waiting for EVO ICL and now that I have it, it was one of the best decisions I could have made for myself,” shared an EVO ICL patient. “Being someone that was legally blind without my contacts and now I am just able to get up and see everything is truly amazing. The procedure was so quick and painless. I was even able to go to work the next day. EVO is the greatest gift I could have received.” Demand for the EVO procedure has more than doubled since 2018 amongst patients, becoming one of the premier solutions for refractive vision correction throughout the world. More than one million and counting EVO lenses have been implanted already worldwide.
“The STAAR EVO ICL lens is a big deal because this improved version of one of our best approaches to correcting nearsightedness and astigmatism is now better than ever,” said Dr. Evan D. Schoenberg, Director of Refractive Services at Georgia Eye Partners. “It provides excellent clarity of vision, even when treating prescriptions twice as high as would be safe with LASIK, does not cause dry eye, and is even reversible if desired. The short, painless procedure has been performed outside the USA over a million times with a 99.4 percent satisfaction rate. This FDA approval means a huge new opportunity for our patients at Georgia Eye Partners!”
EVO ICL Benefits
The procedure corrects a wide range of eye prescriptions quickly and effectively, delivering excellent night vision and even built-in UV protection. It is designed to provide permanent vision correction, although it is both removable and replaceable when needed. EVO is an ideal option for patients who don’t prefer glasses or contact lenses and are not candidates for laser eye surgery.
“For years, our patients have been able to enjoy their ICL lens to correct nearsightedness and astigmatism and now we are very excited to introduce their new EVO version of the lens,” said Dr. Andrew Feinberg, the Medical Director of the Eye Surgery Center of Georgia, the state-of-the-art ambulatory surgery center for Georgia Eye Partners. “Patients can receive the highest quality vision to correct these refractive errors through a simple one-step surgery without the need for any laser procedures.”
The recovery time for the EVO ICL is very quick, comfortable, and maybe as little as a day, due to the small size of the incision made during the procedure. The tiny incision needed to implant the foldable EVO ICL is located on the far edge of the cornea, where there is little danger of it interfering with vision. Once the lens is implanted, sutures are typically not needed to close the incision, further simplifying the procedure.
Implantable Lenses: Precise Vision Correction With A Legacy Of Success
Visian ICL has been approved in Europe since 1997 and in the U.S. since 2005. In 2018, the addition of the Visian Toric ICL expanded the range of vision which can be treated directly with the lens to include up to 4 diopters of astigmatism. Higher degrees of astigmatism can even be treated by combining the ICL with other procedures. In 2019, we celebrated along with the international vision correction community an important milestone: over 1,000,000 Visian ICLs implanted to date, with studies showing a 99 percent patient satisfaction rate!
EVO ICL: Who Is A Candidate?
Every patient has unique vision correction and eye care needs which is why it’s important to schedule an online or in-person consultation with an eye doctor at Georgia Eye Partners to make an informed decision about the procedure.
You may be an excellent candidate if you:
- Are between the ages of 21 and 45
- Are nearsighted, a.k.a. myopic (-3 D up to -20 D)
- Optionally have astigmatism (up to -4 D)
EVO ICL can be used for patients suffering from dry eye, with thin or abnormal corneas, and in many other situations which might preclude LASIK.